Mojebi, A. (Ali)

Filtering

20211

Settings

Author search.filters.isAuthorOfPublication.96ea46e6-c417-42a4-85fd-963b1e7563e6

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Matching adjusted indirect comparisons of efficacy outcomes foridecabtagene vicleucel (ide-cel, bb2121) versus selinexor þ dexamethasoneand belantamab mafodotin in relapsed and refractory multiple myeloma
    (Taylor & Francis, 2021) Rodriguez-Otero, P. (Paula); Ayers, D. (Dieter); Cope, S. (Shannon); Davies, F. (Faith); Delforge, M. (M.); Mojebi, A. (Ali); Jansen, J.P. (Jeroen P.); Weisel, K. (Katja); Hege, K. (Kristen); Dhanasiri, S. (Sujith)
    Idecabtagene vicleucel (ide-cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the single-arm phase 2 KarMMa clinical trial. Two therapies with distinct mechanisms of action - selinexor plus dexamethasone (Sd) and belantamab mafodotin (BM) - are currently approved in the United States for heavily pretreated patients, including those who are triple-class refractory. To compare ide-cel versus Sd and ide-cel versus BM, matching-adjusted indirect comparisons were performed. Ide-cel extended progression-free survival (PFS) and overall survival (OS) versus both Sd and BM (hazard ratio (HR); 95% confidence interval (CI)). PFS: ide-cel versus Sd, 0.46; 0.28-0.75; ide-cel versus BM, 0.45; 0.27-0.77. OS: ide-cel versus Sd, 0.23; 0.13-0.42; ide-cel versus BM, 0.35; 0.14-0.87. These results suggest ide-cel offers clinically meaningful improvements over currently approved regimens for patients with heavily pretreated RRMM.